EcoDrugPlus

Fkbp Prolyl Isomerase 1a

Ensembl ID : ENSMFAG00000042021
Gene Symbol: FKBP1A
4 Cross references
231 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSMFAG00000000074
Gene Symbol: FYN
4 Cross references
261 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

G Protein-Coupled Receptor 119

Ensembl ID : ENSMFAG00000016138
Gene Symbol: GPR119
2 Cross references
174 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

G Protein-Coupled Receptor 84

Ensembl ID : ENSMFAG00000030281
Gene Symbol: GPR84
2 Cross references
124 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSMFAG00000035912
Gene Symbol: HCK
4 Cross references
205 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Il2 Inducible T Cell Kinase

Ensembl ID : ENSMFAG00000000719
Gene Symbol: ITK
2 Cross references
207 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Janus Kinase 1

Ensembl ID : ENSMFAG00000003493
Gene Symbol: JAK1
4 Cross references
236 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Janus Kinase 2

Ensembl ID : ENSMFAG00000003627
Gene Symbol: JAK2
4 Cross references
265 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Janus Kinase 3

Ensembl ID : ENSMFAG00000034366
Gene Symbol: JAK3
4 Cross references
103 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Kit Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSMFAG00000041033
Gene Symbol: KIT
4 Cross references
265 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Kras Proto-Oncogene, Gtpase

Ensembl ID : ENSMFAG00000047411
Gene Symbol: KRAS
4 Cross references
203 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Lck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSMFAG00000031502
Gene Symbol: LCK
4 Cross references
120 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).